Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b Study of CART-BCMA in Relapsed/Refractory Multiple Myeloma
NCT07458659Phase 1Not yet recruiting
- Sponsor
- Chulalongkorn University
- Start
- Jun 2026
- Primary completion
- Jun 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CART-BCMA in multiple myeloma (MM), sponsored by Chulalongkorn University. Primary endpoints: Safety of CART-BCMA and Incidence of Dose-Limiting Toxicities. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
CART-BCMA
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07458659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07458659.